Kelly N. Fitzgerald
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kelly N. Fitzgerald has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Chung-Han Lee
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
3 shared publications - Robert J. Motzer
Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College , New York, NY 10021
3 shared publications Andrea Knezevic
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
2 shared publicationsDarren R. Feldman
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
2 shared publicationsDavid H. Aggen
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
2 shared publicationsMaria I. Carlo
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
2 shared publications
Latest Publications
- 1 October 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- No. 2
Development of a Culturally Tailored Educational Tool to Increase Somatic Testing Participation Among Black Men With Metastatic Prostate Cancer
PURPOSE: Black patients with metastatic prostate cancer (mPCa) are less likely to receive somatic testing than their White counterparts. Our objective was to develop a culturally tailored educational tool intended to increase somatic testing participation. METHODS: We conducted a multisite qualitative study to develop the tool, informed by the human-centered design (HCD) principles Inspiration and Ideation, and the capability-opportunity-motivation-behavior (COM-B) framework. We approached stakeholders to codesign a prototype, iteratively refined the tool through semistructured interviews with Black patients with mPCa, and identified likes , wishes , questions , and ideas until data saturation. We analyzed interviews via COM-B into barriers/facilitators of two behaviors: (1) tool engagement and (2) somatic testing participation. RESULTS: Four physicians, one genetic counselor, and two patients codesigned an electronic tool, consisting of an 8-minute video of a non-Hispanic Black physician and animations followed by a text-based decision aid. We reached data saturation after interviewing 11 patients (61% of 18 approached). Participants liked the tool's cultural tailoring, wished for more information on somatic testing benefits, and questioned content gaps. Their ideas reflected cost concerns. Ten participants expressed a desire to obtain and/or speak with their oncologist about somatic testing. We identified barriers/facilitators of tool engagement and somatic testing participation, which led to changing the text-based decision aid into a Q&A format and tailoring the content to address race, cost, and biopsy-related concerns. CONCLUSION: HCD and COM-B frameworks enabled the development of a culturally tailored educational tool for Black patients with mPCa. This educational tool was well received and might have contributed to increased interest in somatic testing participation. Further research to evaluate the feasibility, acceptability, and efficacy of the tool in clinical workflows is needed.
- 1 October 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- No. 2
Development of a Culturally Tailored Educational Tool to Increase Somatic Testing Participation Among Black Men With Metastatic Prostate Cancer
PURPOSE: Black patients with metastatic prostate cancer (mPCa) are less likely to receive somatic testing than their White counterparts. Our objective was to develop a culturally tailored educational tool intended to increase somatic testing participation. METHODS: We conducted a multisite qualitative study to develop the tool, informed by the human-centered design (HCD) principles Inspiration and Ideation, and the capability-opportunity-motivation-behavior (COM-B) framework. We approached stakeholders to codesign a prototype, iteratively refined the tool through semistructured interviews with Black patients with mPCa, and identified likes , wishes , questions , and ideas until data saturation. We analyzed interviews via COM-B into barriers/facilitators of two behaviors: (1) tool engagement and (2) somatic testing participation. RESULTS: Four physicians, one genetic counselor, and two patients codesigned an electronic tool, consisting of an 8-minute video of a non-Hispanic Black physician and animations followed by a text-based decision aid. We reached data saturation after interviewing 11 patients (61% of 18 approached). Participants liked the tool's cultural tailoring, wished for more information on somatic testing benefits, and questioned content gaps. Their ideas reflected cost concerns. Ten participants expressed a desire to obtain and/or speak with their oncologist about somatic testing. We identified barriers/facilitators of tool engagement and somatic testing participation, which led to changing the text-based decision aid into a Q&A format and tailoring the content to address race, cost, and biopsy-related concerns. CONCLUSION: HCD and COM-B frameworks enabled the development of a culturally tailored educational tool for Black patients with mPCa. This educational tool was well received and might have contributed to increased interest in somatic testing participation. Further research to evaluate the feasibility, acceptability, and efficacy of the tool in clinical workflows is needed.
- 22 May 2024
- Published by Elsevier in European Urology
- Vol. 86 (2) , 90-94
Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial
- 22 May 2024
- Published by Elsevier in European Urology
- Vol. 86 (2) , 90-94
Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial
- 11 November 2022
- Published by Springer Nature in Nature Reviews Urology
- Vol. 20 (3) , 179-193
Adjuvant therapy options in renal cell carcinoma — targeting the metastatic cascade
Localized renal cell carcinoma (RCC) is primarily managed with nephrectomy, which is performed with curative intent. However, disease recurs in ~20% of patients. Treatment with adjuvant therapies is used after surgery with the intention of curing additional patients by disrupting the establishment, maturation or survival of micrometastases, processes collectively referred to as the metastatic cascade. Immune checkpoint inhibitors and vascular endothelial growth factor receptor (VEGFR)-targeting tyrosine kinase inhibitors (TKIs) have shown efficacy in the treatment of metastatic RCC, increasing the interest in the utility of these agents in the adjuvant setting. Pembrolizumab, an inhibitor of the immune checkpoint PD1, is now approved by the FDA and is under review by European regulatory agencies for the adjuvant treatment of patients with localized resected clear cell RCC based on the results of the KEYNOTE-564 trial. However, the optimal use of immunotherapy and VEGFR-targeting TKIs for adjuvant treatment of RCC is not completely understood. These agents disrupt the metastatic cascade at multiple steps, providing biological rationale for further investigating the applications of these therapeutics in the adjuvant setting. Clinical trials to evaluate adjuvant therapeutics in RCC are ongoing, and clinical considerations must guide the practical use of immunotherapy and TKI agents for the adjuvant treatment of localized resected RCC.
- 11 November 2022
- Published by Springer Nature in Nature Reviews Urology
- Vol. 20 (3) , 179-193
Adjuvant therapy options in renal cell carcinoma — targeting the metastatic cascade
Localized renal cell carcinoma (RCC) is primarily managed with nephrectomy, which is performed with curative intent. However, disease recurs in ~20% of patients. Treatment with adjuvant therapies is used after surgery with the intention of curing additional patients by disrupting the establishment, maturation or survival of micrometastases, processes collectively referred to as the metastatic cascade. Immune checkpoint inhibitors and vascular endothelial growth factor receptor (VEGFR)-targeting tyrosine kinase inhibitors (TKIs) have shown efficacy in the treatment of metastatic RCC, increasing the interest in the utility of these agents in the adjuvant setting. Pembrolizumab, an inhibitor of the immune checkpoint PD1, is now approved by the FDA and is under review by European regulatory agencies for the adjuvant treatment of patients with localized resected clear cell RCC based on the results of the KEYNOTE-564 trial. However, the optimal use of immunotherapy and VEGFR-targeting TKIs for adjuvant treatment of RCC is not completely understood. These agents disrupt the metastatic cascade at multiple steps, providing biological rationale for further investigating the applications of these therapeutics in the adjuvant setting. Clinical trials to evaluate adjuvant therapeutics in RCC are ongoing, and clinical considerations must guide the practical use of immunotherapy and TKI agents for the adjuvant treatment of localized resected RCC.
- 4 November 2022
- Published by Elsevier in European Urology
- Vol. 83 (3) , 195-199
Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations
- 4 November 2022
- Published by Elsevier in European Urology
- Vol. 83 (3) , 195-199
Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations
- Open Access
- 11 March 2022
- Published by Elsevier in European Urology Focus
- Vol. 8 (5) , 1278-1288
Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas
- 11 March 2022
- Published by Elsevier in European Urology Focus
- Vol. 8 (5) , 1278-1288
Open AccessGenomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas
- 23 December 2021
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 63 (3) , 751-754
CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas
The human B-cell marker CD19 is highly expressed in many non–Hodgkin's lymphomas and leukemias, and therefore offer an appealing immunotherapeutic target for cancers of lymphoid origin [1]. Anti-CD...
- 23 December 2021
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 63 (3) , 751-754
CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas
The human B-cell marker CD19 is highly expressed in many non–Hodgkin's lymphomas and leukemias, and therefore offer an appealing immunotherapeutic target for cancers of lymphoid origin [1]. Anti-CD...